The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab

Clinical Rheumatology

Volumn 32, Issue 1, 2013, Pages 123-127

  Hirabayashi, Yasuhiko ^a   Ishii, Tomonori ^b  

^a Hikarigaoka Spellman Hospital   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Boolean; Criteria; DAS28 ESR; Remission; Tocilizumab

Indexed keywords

TOCILIZUMAB;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DAS28; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFORMATION SCIENCE; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; FEMALE; HEALTH STATUS; HUMANS; JOINTS; MALE; MIDDLE AGED; PHYSICAL EXAMINATION; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; ROC CURVE; SEVERITY OF ILLNESS INDEX; SYSTEMS BIOLOGY; TREATMENT OUTCOME;

EID: 84873414653     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2103-4     Document Type: Article

References (9)

1. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
2. Felson DT, Smolen JS, Wells G et al (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573-586
3. Hirabayashi Y, Ishii T, Harigae H (2010) Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheumatol Int 30:1041-1048
4. Iking-Konert C, AringerM,Wollenhaupt J et al (2011) Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis 70:1986-1990
5. Ramji DP, Vitelli A, Tronche F, Cortese R, Ciliberto G (1993) The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 beta, are induced by IL-6 to promote acute phase gene transcription via different mechanisms. Nucleic Acids Res 21:289-294
6. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 68:1516-1523
7. Zhang Z, Fuentes NL, Fuller GM (1995) Characterization of the IL-6 responsive elements in the ã fibrinogen gene promoter. J Biol Chem 270:24287-24291
8. Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT (2010) Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 69:1058-1064
9. Aletaha D, Funovits J, Smolen JS (2011) Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis 70:733-739